Breast Cancer Trials
Select Clinical Trial
Protocol Number: NRG-BR003
Protocol Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Eligibility: Men or women ages 18 and older, diagnosed with HER2 negative triple-negative invasive breast cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: SWOG 1418
Protocol Title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Eligibility: Women ages 18 and older, diagnosis of breast cancer with negative estrogen (ER)- and progesterone-receptor (PR) status, and negative (HER)2 receptor, with disease following therapy before surgery.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: NRG-BR004
Protocol Title: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in first-line HER2-Positive Metastatic Breast Cancer
Eligibility: Men or women, ages 18 and older, diagnosed with HER2 positive adenocarcinoma of the breast with locally recurrent, unresectable disease or metastatic disease.
Contact Information: (910) 715-2200
________________________________________________________________________________________
Protocol Number: URCC16070, NCT 03367572
Protocol Title: Treatment of Refractory Nausea
Eligibility: Men or women ages 18 and older, receiving chemotherapy for breast cancer.
Contact Information: (910) 715-2200